Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17119540 | 0.88 | HDAC1 (0.79) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2381104 | 0.86 | HDAC1 (0.73) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2378893 | 0.86 | HDAC1 (0.73) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2378891 | 0.86 | HDAC1 (0.73) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2381106 | 0.86 | HDAC1 (0.73) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| Trichostatin SCHEMBL19886 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| Trichostatin SCHEMBL446806 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| Trichostatin SCHEMBL675951 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| Trichostatin SCHEMBL446807 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| Trichostatin SCHEMBL16380793 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20170239274-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170189408-A1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2017-07-06 | — | — | US | disclosed |
| US-20170020878-A1 | COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR | NOVARTIS AG (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20160235714-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160228456-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2016-08-11 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9399021-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-07-26 | — | — | US | disclosed |
| US-9271941-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-03-01 | — | — | US | disclosed |
| US-20150342957-A1 | COMBINATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150313906-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-9085622-B2 | Antigen binding proteins | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20140154316-A1 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140037726-A1 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130156779-A1 | NOVEL ANTIGEN BINDING PROTEINS | GLAXO GROUP LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20120302579-A1 | CANCER TREATMENT METHOD | GLAXOSMITHKLINE LLC | 2012-11-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239274-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | HDAC1 128/4885HDAC3 247/4885HDAC4 753/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | HDAC1 67/4885HDAC3 92/4885HDAC4 121/4885 |
| US-20120302579-A1 | CANCER TREATMENT METHOD | MPL, TPO, PROKR1 | HDAC1 4523/4885HDAC3 4472/4885HDAC4 3805/4885 |
| US-20130156779-A1 | NOVEL ANTIGEN BINDING PROTEINS | CD2BP2, HSPBP1, LGALS3BP | HDAC1 3555/4885HDAC3 4264/4885HDAC4 3147/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | HDAC1 2055/4885HDAC3 2478/4885HDAC4 3077/4885 |
| US-20170020878-A1 | COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR | BTK, PIK3CD, PIK3CA | HDAC1 842/4885HDAC3 926/4885HDAC4 1224/4885 |
| US-20140154316-A1 | NOVEL PHARMACEUTICAL COMPOSITION | PHOSPHO1, PLA2G2C, TTR | HDAC1 1261/4885HDAC3 481/4885HDAC4 1122/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | HDAC1 67/4885HDAC3 92/4885HDAC4 121/4885 |
| US-20160228456-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | HDAC1 143/4885HDAC3 304/4885HDAC4 994/4885 |
| US-20160235714-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | AR, PIK3CA, NR5A1 | HDAC1 7/4885HDAC3 16/4885HDAC4 67/4885 |
| US-20140037726-A1 | NOVEL PHARMACEUTICAL COMPOSITION | PHOSPHO1, PLA2G2C, TTR | HDAC1 1261/4885HDAC3 481/4885HDAC4 1122/4885 |
| US-20150313906-A1 | COMBINATION | EZH2, BMI1, DOT1L | HDAC1 16/4885HDAC3 25/4885HDAC4 54/4885 |
| US-20170189408-A1 | NOVEL PHARMACEUTICAL COMPOSITION | TTR, PHOSPHO1, PLA2G2C | HDAC1 1427/4885HDAC3 584/4885HDAC4 1127/4885 |
| US-20150342957-A1 | COMBINATION | PAICS, CA6, CA5A | HDAC1 67/4885HDAC3 19/4885HDAC4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.